Valeo Pharma Inc.
VPHIF
$0.0469
-$0.0471-50.11%
OTC PK
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.68% | -6.95% | -6.12% | -3.50% | -9.40% |
| Total Depreciation and Amortization | 10.33% | 32.98% | 63.79% | 113.79% | 184.59% |
| Total Amortization of Deferred Charges | -44.51% | -44.51% | -44.51% | -66.65% | 3.48% |
| Total Other Non-Cash Items | 3.08% | -32.47% | -21.90% | -27.98% | 118.41% |
| Change in Net Operating Assets | 319.99% | 280.35% | 225.07% | 135.41% | -1,055.38% |
| Cash from Operations | 83.97% | 77.75% | 90.97% | 47.72% | -13.98% |
| Capital Expenditure | 75.90% | 47.85% | -28.59% | -26.16% | 52.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -167.56% | 52.26% | 33.73% | 28.22% | 139.48% |
| Cash from Investing | -177.58% | 52.00% | 30.94% | 25.43% | 132.91% |
| Total Debt Issued | 106.81% | 210.50% | 210.50% | -80.93% | -167.58% |
| Total Debt Repaid | -159.71% | -160.01% | -146.22% | -151.63% | 167.97% |
| Issuance of Common Stock | 391,900.00% | 1,148.41% | 894.92% | 894.92% | -99.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.71% | -100.73% | -100.62% | -100.62% | 1,193.13% |
| Cash from Financing | 357.77% | -84.40% | -82.55% | -89.61% | -98.24% |
| Foreign Exchange rate Adjustments | -49.46% | -87.53% | -91.76% | -93.75% | 607.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.44% | -154.23% | -136.57% | -169.15% | -192.34% |